Disitamab vedotin |
Catalog No.GC64039 |
디시타맙 베도틴(RC48)은 절단 가능한 링커를 통해 세포독성제 모노메틸 아우리스타틴 E(MMAE)에 접합된 인간 표피 성장 인자 수용체 2(HER2)에 대한 모노클로날 항체를 포함하는 항체-약물 접합체(ADC)입니다. Disitamab vedotin은 항종양 면역을 향상시킵니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2136633-23-1
Sample solution is provided at 25 µL, 10mM.
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity[1].
The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].
[1]. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.
[2]. Jiang J, et al. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37.
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *